ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1344

Patient-reported Outcomes in Lupus Low Disease Activity State: Impact of Fatigue
Abstract Number: 1345

Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?
Abstract Number: 1346

“Finally, I Can Do Something About It Myself”: A Process Evaluation of the Plants for Joints Lifestyle Intervention
Abstract Number: 1347

Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Abstract Number: 1348

We Asked Patients and Families: What Is the Job of a Pediatric Rheumatologist?
Abstract Number: 1349

Priority Educational Topics to Deliver Information About Immune Checkpoint Inhibitors for Patients with Cancer and a Pre-Existing Autoimmune Disease
Abstract Number: 1350

A Prospective Study on Pain Associated with Injection of Needles: PAIN Study
Abstract Number: 1351

Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study
Abstract Number: 1352

Improving Completion Rates of Routine Mental Health Screening for Depression and Anxiety in Paediatric Lupus Outpatient Clinic to Enhance Patient Mental Health Care
Abstract Number: 1353

Dietary Practices and Beliefs of Patients with Rheumatic Diseases and Relationship with Symptoms: Results of a Multicenter Cross-sectional Study
Abstract Number: 1354

Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application
Abstract Number: 1355

Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials
Abstract Number: 1356

Patient-perceived Disease Burden and Self-reported Medication Adherence in Systemic Autoimmune Diseases: A Monocentric Observational Study
Abstract Number: 1357

The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage
Abstract Number: 1358

Adherence to Early DMARD Strategies in Newly Diagnosed RA Patients Seen in Routine Care: Results from the Canadian Early Arthritis Cohort Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].